The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3Ll) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
本发明的特点是改进的化合物,特别是(I)利用与药物敏感性相关的
生物标志物(例如PDE3A、SLFN12和/或CREB3Ll)来识别患有癌症的患者的方法,并因此使用本发明的药剂(例如本文披露的化合物1-6)治疗分层患者人群。